Healthcare Jul 30, 2021 09:23 AM (GMT+8)
Yiouda health learned on the 30th that recently, Beijing Daxiang Technology Co., Ltd. (hereinafter referred to as "Daxiang technology") announced to obtain tens of millions of yuan of a + round financing support. It is understood that this round of financing is led by Hongtai fund and followed by benevolent capital, and the old shareholders CDH VGC and Furong investment continue to increase.
Zhou Yu, CEO of Daxiang technology, revealed that in just three months, two consecutive rounds of financing totaled 100 million yuan. In addition to originally intended to accelerate the layout of organ chip industry chain, it will also focus on promoting the iteration of organ like chip technology and provide a high-quality and high-throughput model for the R & D of innovative drugs in the fields of cancer, neurodegenerative diseases and inflammatory diseases, At the same time, improve the standardized cultivation system of organoids and its application in the field of personalized precision medicine.
In August 2020, Daxiang Technology launched three domestic organ chips with completely independent intellectual property rights, which is also the first time for domestic enterprises to launch relevant commercial products. At present, the R & D team of Daxiang technology has successfully prepared organoid chip models, high bionic tumor microenvironment models and other organoid pathological models from a variety of tumor tissues, which are suitable for drug R & D and clinical transformation in many disease fields. In addition, according to Daxiang technology, the prospective clinical research on the consistency between the drug sensitivity test results and clinical application results carried out by the company and its partners is also progressing smoothly.
This text is a result of machine translation.